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Abstract
 
Splenic B lineage cells expressing recombination activation genes (RAG
 
1
 
)
 
 
 
in mice immunized
with 4-hydroxy-3-nitrophenyl-acetyl coupled to chicken 
 
g
 
-globulin (NP-CGG) and the adju-
vant aluminum-hydroxide
 
 (
 
alum) have been proposed to be mature B cells that reexpress RAG
after an antigen encounter in the germinal center (GC), a notion supported by findings of
RAG expression in peripheral B lymphocyte populations activated in vitro. However, recent
studies indicate that these cells might be immature B cells that have not yet extinguished RAG
expression. Here, we employ RAG2–green fluorescent protein (GFP) fusion gene knock-in
mice to show that RAG
 
1
 
 B lineage cells do appear in the spleen after the administration of
alum alone, and that their appearance is independent of T cell interactions via the CD40 path-
way. Moreover, splenic RAG
 
1
 
 B lineage cells were detectable in immunized RAG2-deficient
mice adoptively transferred with bone marrow (BM) cells, but not with spleen cells from
RAG
 
1
 
 mice. Although splenic RAG
 
1
 
 B cells express surface markers associated with GC B
cells, we also find the same basic markers on progenitor/precursor BM B cells. Finally, we did
not detect RAG gene expression after the in vitro stimulation of splenic RAG
 
2
 
 mature B cells
with mitogens (lipopolysaccharide and anti-CD40) and cytokines (interleukin [IL]-4 and IL-7).
Together, our studies indicate that RAG
 
1
 
 B lineage cells from BM accumulate in the spleen
after immunization, and that this accumulation is not the result of an antigen-specific response.
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Introduction
 
During B cell development in the bone marrow (BM),
 
1
 
 Ig
heavy (IgH) and Ig light (IgL) chain variable region genes
are assembled from germline variable (V), diversity (D), and
joining (J) gene segments by a process referred to as V(D)J
recombination (for a review, see reference 1). V(D)J re-
combination is absolutely dependent on the expression of
the products of recombination activating gene (RAG)1 and
RAG2, which together initiate V(D)J recombination by
recognizing and cleaving the recombination signal se-
quences that flank different V, D, and J coding segments
(for a review, see reference 1).
RAG1 and RAG2 are coordinately expressed during B
cell development, as sequential IgH D to J
 
H
 
 and V
 
H
 
 to DJ
 
H
 
occurs in B220
 
lo
 
CD43
 
1
 
IgM
 
2
 
 progenitor B cells, and IgL
V
 
L
 
 to J
 
L
 
 rearrangements take place in B220
 
lo
 
CD43
 
lo
 
IgM
 
2
 
precursor B cells (2–6). The production of IgH and IgL
chains from functionally rearranged genes leads to the ex-
pression of surface IgM and developmental progression to
the immature B cell stage. Immature BM B cells are
B220
 
lo
 
IgM
 
lo
 
IgD
 
2
 
heat stable antigen (HSA)
 
hi
 
pB130-140
 
1
 
and many have continued RAG expression (7–12). As im-
mature B cells develop into the transitional stage, they
downregulate RAG and migrate to the spleen (6, 11, 12).
During development, only a small fraction of the newly
generated, immature B cells join the pool of long-lived ma-
 
ture, B220
 
hi
 
IgM
 
lo
 
IgD
 
hi
 
HSA
 
lo
 
pB130–140
 
2
 
 splenic B cells; at
the mature B cell stage, RAG expression is virtually unde-
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tectable (9–12; for a review, see reference 13). Thus, most
B cells in a normal spleen of an unimmunized adult mouse
do not express RAG.
Very young mice (e.g., 
 
,
 
4 wk) have a substantial popu-
lation of splenic, RAG
 
1
 
 B lineage cells that presumably re-
present pre-B
 
/
 
immature B cells present from remnants of
splenic lymphopoiesis that occurs before the shift to adult BM
(11, 12). Older mice (
 
.
 
9 wk) immunized with 4-hydroxy-
3-nitrophenyl-acetyl coupled to chicken 
 
g
 
-globulin (NP-
CGG), and an adjuvant such as aluminum-hydroxide
(alum), develop RAG
 
1
 
, IgM
 
2 
 
or IgM
 
lo
 
, B220
 
lo
 
, GL-7
 
1
 
 
 
or
GL-7
 
2
 
, pB130-140
 
1
 
, peanut agglutinin (PNA)
 
1
 
, HSA
 
1
 
splenic B lineage cells that phenotypically resemble pre-B/
immature B cells (11, 12, 14, 15). Some of these RAG
 
1
 
spleen cells have been reported to localize to the germinal
center (GC) (14, 16, 17). At least three, not necessarily mu-
tually exclusive, hypotheses have been proposed concern-
ing the origin of the B220
 
lo
 
 RAG
 
1
 
 splenic B cells. One
proposes reexpression of RAG and other markers of early
B cell developmental stages in mature, splenic GC B cells
after activation in response to antigens (14–21). The second
involves generation of pre-B
 
/
 
immature B cells from resid-
ual hematopoietic islands in the spleen (11, 22–24). The
third involves the emigration of RAG
 
1
 
 pre-B/immature B
cells from the BM to the spleen after immunization (11, 12,
22, 23).
Secondary IgH and IgL V region gene rearrangements
have been detected in various transgenic B cells (for re-
views, see references 22, 25), such as IgH and IgL site-
directed mutant B cells (for reviews, see references 22, 25)
and primary normal B cells (14–17, 19, 20, 26–28). These
findings provided evidence that secondary V
 
L
 
 to J
 
L
 
 rear-
rangements or IgH V gene replacements (receptor editing)
in newly generated, BM B cells may contribute substan-
tially to the generation of the Ab repertoires and to the es-
tablishment of tolerance (22). The occurrence of a related
mechanism of secondary, antigen-dependent V gene rear-
rangements in peripheral B cells, referred to as “receptor
revision,” was hypothesized based on the finding of RAG
 
1
 
B lineage cells in the spleens of immunized mice (11, 12,
14–16) and supported by findings of V(D)J recombination
in splenic B cells after immunization (15, 21) or in vitro ac-
tivation (17–20). However, recent studies using a RAG re-
porter transgenic mouse line (see below) demonstrated that
RAG
 
2
 
 splenic B cells could not be induced to express
RAG in vivo or in vitro, questioning the notion that RAG
genes can be reexpressed in mature B cells (12). In addi-
tion, work with RAG2–green fluorescent protein (GFP)
fusion gene knock-in mice indicated that the splenic
RAG
 
1
 
 cells were similar in phenotype to BM
 
 
 
pro/pre-B
cells, supporting the possibility that the RAG
 
1
 
 cells that
appear after immunization may derive from immature BM
B lineage cells (11).
V(D)J recombination absolutely depends on RAG ex-
pression (29, 30). Therefore, to easily identify live cells that
express RAG in various populations, we generated reporter
mice in which a RAG2–GFP fusion gene replaced the en-
dogenous RAG2 coding exon (11). The advantages of this
 
approach are that expression of the RAG2–GFP fusion
protein appears to closely mimic that of the endogenous
RAG protein during normal development and that the fu-
sion protein functions to support V(D)J recombination suf-
ficient to provide normal lymphocyte development (11).
However, a limitation of the RAG2–GFP fusion gene
mouse model is a relatively low GFP signal (11). In parallel
experiments, others have generated either transgenic mice
in which a GFP protein was driven by RAG gene-regula-
tory regions (NG-BAC [12, 23]) or a mouse in which GFP
was targeted in place of the RAG1 coding sequence
(RAG1/GFP replacement [31]). Whereas the NG-BAC
transgenic or RAG1/GFP replacement mice provide a
much stronger signal, GFP alone appears to be more stable
than endogenous RAG and thus the reporter gene expres-
sion may extend somewhat beyond normal RAG protein
expression (12, 23, 31). Analyses of the different strains of
RAG reporter mice have yielded largely similar conclu-
sions and, when viewed together, may provide information
beyond that available with individual approaches (23; see
Discussion).
To further elucidate the nature of peripheral RAG
 
1
 
 B
lineage cells in immunized mice, we employed the RAG2–
GFP fusion mice and other approaches to identify the
source of the splenic RAG
 
1
 
 lymphocytes after immuniza-
tion and to further characterize the conditions that lead to
their appearance.
 
Materials and M
 
ethods
 
Mice.
 
CD40L
 
2
 
/
 
2 
 
(C57BL/6 [B6], 129 S-Tnfsf5, or B6
S-Tnfsf5; The Jackson Laboratory) (32) were bred with RAG2
 
-
 
GFP mice (11). 129 mice and C3H mice were obtained from
Taconic Farms.
 
Flow Cytometry.
 
 
 
Single-cell suspensions were stained with
FITC-, PE-, CyChrome (CyC)-, and biotin (bi)-conjugated Abs
and analyzed by a FACSCalibur™ (Becton Dickinson) as de-
scribed (11). The following Abs were used (BD PharMingen and
Southern Biotechnology Associates, Inc.): FITC
 
–
 
anti-GL7; PE
 
–
 
anti-CD43 (S7), -IgM
 
a 
 
(Igh-6a), 
 
2
 
c-kit (2B8), -IgD (11
 
-
 
26),
-IgM (1B4B1), -CD24 (M1/69), -CD25 (PC61), -CD4 (RM4
 
-
 
5), 
 
2
 
GR-1 (RB6
 
-
 
8C5), -F480 (provided by L.A. Herzenberg,
Stanford School of Medicine, Stanford, CA), -
 
k
 
 (187.1), -
 
l
 
(JC5-1), -CD23 (B3B4), and 
 
2
 
c-kit (2B8); CyC
 
–
 
anti-B220
(RA3
 
-
 
6B2), -CD8 (53
 
-
 
6.7), and 
 
2
 
syndecan-1 (CD138, 281
 
-
 
2);
bi
 
–
 
anti-MAC-1 (M1/70), -F480 (provided by L.A. Herzenberg),
-PNA, 
 
2
 
pB130
 
-
 
140 (493) (provided by M. Carroll, Harvard
Medical School, Boston, MA and prepared by the authors), and
bi
 
–
 
GL-7 (provided by G. Kelsoe, Duke University Medical
School, Durham, NC). Streptavidin-PE, -CyC, and -allophyco-
cyanin were used to reveal bi-conjugated Abs. For most FACS
 
®
 
plots, 
 
$
 
100,000 events were collected; dead cells were excluded
by forward scatter gating. Data were analyzed with either
CELLQuest™ (Becton Dickinson) or FlowJo (Tree Star, Inc.)
software. Cell sorting was performed on a MoFlo machine (Cy-
tomation) or an Epics Altra (Beckman Coulter).
 
Immunizations.
 
 
 
RAG2
 
1
 
/
 
1
 
, RAG2
 
1
 
/GFP
 
, and RAG2
 
GFP/GFP
 
mice (10
 
–
 
13 wk old) were immunized intraperitoneally with a
single dose of 100 
 
m
 
g of NP-CGG, provided by G. Kelsoe or
prepared from individual components (Biosearch Technologies, 
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Inc.) as described previously (33), that had been precipitated in
alum as described previously (15), except that 1 ml (as opposed to
300 
 
m
 
l) of the final suspension was used for intraperitoneal im-
munizations. Spleens were taken at times indicated after immuni-
zation and dissociated into single-cell suspensions for FACS
 
®
 
analysis. Immunizations had no effect on thymus cellularity or T
cell subsets on days 8 and 16 after immunization (data not
shown).
 
Splenic B Cell Cultures. 
 
Splenic B cells were purified from
single-cell suspensions of either 10
 
–
 
15-wk-old male C3H mice,
CD40L
 
2
 
/
 
2
 
 mice, or RAG2
 
–
 
GFP mice (11) by sorting (MoFlo;
Cytomation) based on B220 and IgD surface expression or by cy-
totoxic T cell depletion as described (19). Culture conditions
were as published (19). In brief, splenic B cell preparations were
cultured at 1
 
–
 
3 
 
3 
 
10
 
6
 
 cells/ml for 2
 
–
 
3 d in 1 ml RPMI 1640
medium (10% FCS, 10
 
2
 
5
 
 M 2-mercaptoethanol, 100 U/ml peni-
cillin G, and 100 
 
m
 
g/ml streptomycin) with 20 mg/ml LPS from
Escherichia coli 055:B5 (Sigma-Aldrich), 1 mg/ml anti-CD40
mAbs (BD PharMingen), 10 ng/ml recombinant murine IL-4
(PeproTech), or 10 ng/ml recombinant murine IL-7 (Pepro-
Tech) as indicated.
Reverse Transcription PCR Analysis. Total RNA from splenic
cultures was isolated using TRIzol (Life Technologies) or
TriPure (Roche Molecular Biochemicals) reagent, reverse tran-
scribed with SuperScript II (Life Technologies) or Omniscript
(QIAGEN), and primed with random hexamers according to the
directions of the manufacturer (Life Technologies). PCR reac-
tions (25 ml) contained 5 ml of the cDNA preparation, 3 pmol of
both sense and antisense oligonucleotide primer, 0.2 mM of each
dNTP, 2 mM MgCl2, and 1 U Taq DNA polymerase in 13
PCR buffer (QIAGEN). Intron spanning primers for RAG1,
RAG2, TdT, l-5, Vpre-B, and b-actin were as described by Li
et al. (4), except that the l-5 sense primer was 59-CTT-
GAGGGTCAATGAAGCTCAGA-39. Primers for detection of
e and g-2b IgH germline transcripts were as published previously
(34). Primers for the amplification of glyceraldehyde 3-phos-
phate dehydrogeanse (GAPDH) were GAPDH-S (59-TCCA-
CCACCCTGTTGCTGTA-39) and GAPDH-A (59-ACCACA-
GTCCATGCCATCAC-39). PCR reactions were performed on
a GeneAmp thermocycler (model 9600; PerkinElmer) with the
following conditions: 3 min at 948C; 18–45 cycles for 30 s at
948C, 15 s at 608C (or 588C for e and g-2b), and 45 s at 728C;
and finally, 10 min at 728C. In every experiment, the cycle num-
ber was titrated for every primer pair to be in the exponential
phase of amplification (with the exception of BM samples, where
the signal intensity relative to spleen samples was determined by
serial dilution). PCR products were resolved on 2% agarose gels
and visualized by ethidium bromide staining.
ELISA Analysis.  Detection of anti–NP-specific Abs was
done as described previously (35). An anti-NP IgG1 standard
mAb (PE-VHCg1 [33]) was provided by G. Kelsoe.
Adoptive Transfer.  RAG2GFP/GFP spleen, RAG2GFP/GFP BM,
129 spleen, or 129 BM cells from pooled 9–16-wk-old mice were
adoptively transferred intravenously into 5-wk-old RAG22/2
recipients. Donor spleen cells from old RAG2–GFP mice did
not express GFP (11). Ly9.1 was used to distinguish recipient
(Ly9.12) B220lo cells from those of the donor (Ly9.11). Mice
adoptively transferred with BM received 1.8 3  107 cells per
mouse and mice adoptively transferred with spleen received 9.2 3
107 cells per mouse. There were four to five mice in each group,
Figure 1. The appearance of RAG-expressing
B220lo cells in the spleen after immunization is inde-
pendent of antigen and the CD40 pathway. Splenic
cells from 10-wk-old CD40L2/2 or wt mice immu-
nized intraperitoneally with alum alone, NP-CGG
with alum, or PBS were analyzed at days 8 and 16 after
injection and analyzed for GL-7 and B220 expression.
The percentages of cells out of total live lymphocytes
for the gated populations are shown. FACS® plots are
shown from representative mice of five experiments
where the indicated number of mice was analyzed at
days 8 and 16 for each treatment: wt NP-CGG/alum
day 8 n 5 10, day 16 n 5 10; CD40L2/2 NP-CGG/
alum day 8 n 5 2, day 16 n 5 2; wt alum day 8 n 5 4,
day 16 n 5 12; CD40L2/2 alum day 8 n 5 5, day 16
n 5 5; naive n 5 12, where wt mice were either 129 or
RAG2–GFP. The mean and standard deviation for the
percentages of subsets out of total live lymphocytes ob-
served on day 8 and day 16 are as follows: at day 8, wt
NP-CGG/alum mice exhibited 1.8 6 0.8% B220hiGL-
711 cells (gate A) compared with percentage values of
0.12 and 0.16 for the CD40L2/2 mice immunized
with NP-CGG/alum, 0.54 6 0.2 for wt alum, 0.14 6
0.05 for CD40L2/2 alum, and 0.43 6 0.3 for naive
mice; at day 16, the B220loGL-71 subset (gate B) was
observed at percentage values of 6.5 6 6.1 for wt NP-
CGG/alum, percentage values of 0.77 and 12 for the
CD40L2/2 mice immunized with NP-CGG/alum, 3.0 6
2.8 for wt alum, 6.3 6 2.3 for CD40L2/2 alum, and
0.5 6 0.5 for naive mice; at day 16, the B220loGL-72
subset (gate C) was observed at percentage values of
8.0 6 5 for wt NP-CGG/alum, percentage values of
5.9 and 9.6 for the CD40L2/2 mice immunized with
NP-CGG/alum, 4.8 6 1.6 for wt alum, 6.4 6 2.4 for
CD40L2/2 alum, and 2.9 6 1.3 for naive mice.1748 Appearance of RAG1 BM Cells in Spleens of Immunized Mice
three of which were immunized the day after transfer with 100
mg NP-CGG/alum, while the remaining mice served as naive
controls. In addition, three 10-wk-old RAG2GFP/GFP and three
10-wk-old 129 mice were immunized as positive controls. Unim-
munized 10-wk-old RAG2GFP/GFP and 129 mice served as naive
controls. RAG22/2 mice served as a negative control. Spleen and
BM cells were analyzed by FACS® for the presence of RAG2–
GFP1 cells in the case of RAG2GFP/GFP transferred mice, and
B220lo4931 or B220loGL-71 cells in the case of both RAG2GFP/GFP
and 129 transferred mice after gating on Ly9.11 cells.
Results
Appearance of RAG1 Splenic B Cells after Immunization Is
Independent of Antigen and the CD40 Pathway. RAG1
splenic B lineage cells appear in the spleen of mature ($9
wk) mice after immunization with the antigen NP-CGG
(11, 12, 23). To characterize the requirement for antigen
and T cell help with respect to the appearance of this cell
population, we immunized wild-type (wt) and CD40L2/2
mice with alum in the presence or absence of NP-CGG.
As expected, on day 8 after immunization we detected a
population of B220hiGL-711 splenic, B lineage cells not
seen in naive animals (11, 14, 15; Fig. 1, gate A). Appear-
ance of this “GC B cell population” (14, 15) was depen-
dent on immunization with antigen and was absent in
CD40L2/2 mice, consistent with a requirement for helper
T cells and an intact CD40 pathway for the initiation of the
GC reaction (24, 32, 36). We also found considerable
numbers of splenic B220lo cells on day 16, but not on day
8, after immunization (11, 12, 15); these cells can be subdi-
vided into B220loGL-71 and B220loGL-72 subpopulations
(Fig. 1, gates B and C, respectively [11]). Significantly,
B220lo cells appeared on day 16 both in wt mice and in
CD40L2/2 mice injected with alum alone (Fig. 1). Alum
injection of both wt and CD40L2/2 mice also resulted in
spleens containing high numbers of granulocytes (data not
shown). We concluded that the B220lo B lineage cells that
appear in the spleen on day 16 after immunization are part
of a generalized response to the alum adjuvant in the ab-
sence of antigen or CD40L-mediated T cell interactions.
To assess whether the splenic B220lo B cell population
induced 16 d after the injection of alum was RAG1, we as-
sayed for the expression of the RAG2–GFP fusion protein
in RAG2–GFP mice injected with alum, with or without
NP-CGG (Fig. 2). The B220lo B cells appearing in the
spleen after the application of alum alone on day 16 clearly
were RAG2–GFP1(Fig. 2 A). To test whether B220lo B
cells induced by alum plus NP-CGG in CD40L2/2 mice
were RAG1, we immunized RAG2–GFP mice bred into
the CD40L2/2 background (Fig. 2 B). Again, we observed
that the B220lo B cells induced in the CD40L2/2 back-
ground 16 d after immunization were RAG1 and that the
size of this population was similar to that induced in a wt
background (compare Fig. 2, B and A). The latter finding
clearly shows that generation of the RAG1 splenic B lin-
eage cells occurs in a fashion that is independent of the
pathways required for GC formation. Neither mature
B220hiGL-72/lo splenic B cells nor the antigen-dependent
B220hiGL-711 cells appearing on day 8 expressed RAG
even after immunization with the antigen NP-CGG (data
not shown, and reference 11).
To further characterize the RAG1 splenic, B lineage
subsets that appear in the late stages of the immune re-
sponse, we sorted splenic B cell populations from CD40L2/2
mice on day 16 after alum injection (Fig. 2 C). Reverse
transcription (RT)-PCR analysis of RNA isolated from
unsorted, B220hi, B220loGL-72, and B220loGL-71 popula-
tions was performed to examine the expression of several
Figure 2. RAG2–GFP1 cells are present in the
spleen on day 16 after alum immunization alone and in
the absence of the CD40L pathway. (A) RAG2GFP/GFP
mice (13 wk old) were immunized intraperitoneally
with alum or PBS; their splenic cells were analyzed on
day 16 for RAG2–GFP expression by FACS®. Per-
centages of B220loRAG2–GFP1 cells out of total live
lymphocytes are shown on FACS® plots of representa-
tive mice of two experiments representing four
RAG2–GFP mice which received alum and two naive
mice analyzed at day 16. (B) Splenic cells from 10-wk-
old CD40L2/2RAG21/GFP mice immunized with NP-
CGG and alum were analyzed on day 16 for RAG2–
GFP expression by FACS®. Percentages of B220lo
RAG2–GFP1 cells out of total live lymphocytes are
shown for representative mice of two experiments rep-
resenting three immunized mice of the CD40L2/2
background and three naive mice of the 129 back-
ground. (C) RNA was purified from unsorted, sorted
B220hi (reanalysis 95% purity), sorted B220loGL-72
(reanalysis 80% purity), and sorted B220loGL-71 cells
(reanalysis 90% purity) from three 12-wk-old, day 16
CD40L2/2 alum-immunized mice and used for RT-
PCR analysis of RAG1, RAG2, TdT, l-5, and Vpre-B.
b-Actin was used as a control to ensure equivalent
amounts of RNA. One out of five representative ex-
periments is shown.1749 Gartner et al.
progenitor/precursor B cell markers. As expected, RAG1
and RAG2 expression was extremely low to undetectable
in the unsorted cells (Fig. 2 C, lane 1) and the B220hi ma-
ture B cell populations (Fig. 2 C, lane 2). In contrast, RAG
expression was strongly enriched in the B220loGL-72 and
B220loGL-71 subsets (Fig. 2 C, compare lanes 3 and 4 with
lane 1). Of note, transcripts from several other pro/pre-B–
specific genes (including TdT, l-5, and Vpre-B) were also
enriched in the B220lo population (Fig. 2 C). Similar results
were obtained with B220loGL-72 and B220loGL-71 popu-
lations sorted from CD40L1/1 mice immunized with NP-
CGG and alum (data not shown).
We concluded that the splenic B220lo subsets appearing
during the late stages of the immune response express the
RAG genes together with markers characteristic of devel-
oping pro-B and pre-B cells in the bone marrow. Further-
more, RAG expression does not require specific antigens
or an intact CD40 pathway.
Common Surface Marker Expression on Developing BM B
Cells and Postimmunization RAG2–GFP1 Splenic B-Lineage
Cells. To determine whether the RAG1 splenic B cells
expressed any additional developmental B cell markers, we
compared surface marker expression on B220lo cells in the
spleen and on the BM of RAG2–GFP mice. The general
expression patterns of the B220loGFP1 and B220loGFP2
subsets in the spleen after NP-CGG and alum administra-
tion closely correlated with those of the corresponding
pro- and/or pre-B populations in the BM (Fig. 3). Thus,
B220loGFP1 and B220loGFP2 cells in the spleen uniformly
expressed the immature B cell marker pB130-140 (8), the
BM B cell, and the Ab-secreting cell markers PNA (37)
and syndecan-1 (38). Similarly, GL-7 expression levels
were essentially the same on both subsets, with GL-72 cells
being relatively more abundant in the splenic B220loGFP2
compartment. Of note, most of the B220loGFP1 cells ex-
pressed little or no IgM, whereas the relative contribution
of IgM1 cells was greater in the B220loGFP2 compartment,
consistent with this subset representing a later develop-
mental stage  (see legend to Fig. 3). Notably, splenic
B220loGFP1 and B220loGFP2 cells both expressed low lev-
els of CD43, with only a small subset being CD43hi, consis-
tent with a predominantly pre-B cell phenotype of the
splenic B220lo populations. Together, the RT-PCR and
FACS® analysis of the B220lo subsets show that the RAG-
expressing cells detectable in the spleen in the late stages of
an immune response predominantly resemble BM pre-B
cells, with a smaller number potentially representing pro-B
and immature B cells.
Adoptive Transfer of RAG2–GFP Cells Confirm That
RAG1  Developing BM B Cells Populate the Spleen after Immu-
nization. The characteristics of splenic RAG1 B cells are
consistent with the notion that they arise from B lineage
BM cells. To directly test whether BM cells can give rise to
splenic RAG1 cells after immunization, we performed
adoptive transfer experiments. BM and spleen cells from ei-
ther RAG2–GFP or 129 wt donor mice were transferred
intravenously into RAG22/2 mice; the following day, the
recipients were either immunized with NP-CGG and alum
or left unimmunized. By day 16, splenic RAG1 cells were
observed only in immunized recipient mice that received
RAG2–GFP BM (Fig. 4). Similarly, immunized mice that
received BM cells from 129 wt mice contained the splenic
B220lopB130-1401 population enriched in RAG1 cells
(data not shown). No splenic B220lopB130-1401cells or
GFP1 cells were detectable in mice that received 129 wt or
RAG2–GFP spleen cells. Immunized control mice and im-
munized recipients of spleen cells produced antigen-spe-
cific Abs after immunization, whereas the BM recipients
did not, probably due to insufficient numbers of mature T
and/or B cells at the time of immunization (data not
shown).
These results separate the antigen-specific immune re-
sponse, which leads to the production of Abs, from the an-
tigen-independent response that leads to the appearance of
RAG1 splenic B cells. While we cannot exclude the possi-
Figure 3. B220lo cells present in immunized spleen resemble pro/pre/
immature B cells. Splenic and BM RAG2–GFP1 and RAG2–GFP2 cells
from NP-CGG/alum–immunized (intraperitoneally) mice at day 16 were
analyzed for cell surface expression by staining for pB130-140, GL-7,
CD43, IgM, PNA, syndecan-1, and B220. Histograms depicting the ex-
pression of the various cell surface markers generated from the RAG2–
GFP1 gated cells (shaded) are overlayed with histograms generated from
RAG2–GFP2 gated cells (line). In the CD43 histogram panels, B220hi
gated cells were used to generate CD432 histograms as a reference (dotted
line). Percentages of RAG2–GFP1 and RAG2–GFP2 cells out of total
live B lymphocytes are shown. In the spleen, 10% of GFP1 cells were
IgM1 and 32% of GFP2 cells were IgM1. In the BM, 5% of GFP1 cells
were IgM1 and 30% of GFP2 cells were IgM1. Gates are as indicated on
the IgM histogram panels. FACS® plots are shown from representative
mice of two experiments representing eight RAG2–GFP immunized
mice and four 129 naive mice. BM RAG2–GFP1 and RAG2–GFP pop-
ulations exhibit the same respective cell surface phenotype regardless of
whether cells were analyzed from immunized or naive mice. BM or
splenic GFP1 and GFP2 cells from mice immunized with alum alone ex-
hibited a similar phenotype as the data shown.1750 Appearance of RAG1 BM Cells in Spleens of Immunized Mice
stimulated B cells (Fig. 5 B, lane 2) and declined further in
samples stimulated with LPS alone (Fig. 5 B, lane 3). Sur-
prisingly, no induction of RAG1 or RAG2 transcripts was
detected in cultures stimulated with LPS plus IL-4 (Fig. 5
B, lane 4) or LPS plus IL-7 (Fig. 5 B, lane 5). Levels of
TdT and l-5 transcripts paralleled those of RAG tran-
scripts. As a positive control, we demonstrated that the ex-
pression of germline Ce or Cg2b transcripts was appropri-
ately induced by LPS or LPS and IL-4 (Fig. 5 B).
To exclude the possibility that the b-actin transcript sig-
nal used for normalization biased against the detection of
RAG upregulation in various culture conditions, we com-
pared the transcript levels of GAPDH and Mb-1, two other
markers commonly used for normalization, in b-actin-
adjusted samples (Fig. 5 C). Whereas b-actin and Mb-1
levels were consistent under the various culture conditions,
GAPDH levels were quite low in uncultured B cells and
increased after activation, making this an inappropriate
marker for standardization (Fig. 5 C, lane 1). Overall, the
decrease in RAG expression after activation, coupled with
the correlation between the RAG, TdT, and l-5 transcript
levels, suggests that the preexisting RAG levels in the un-
cultured samples result from a small number of developing
B cells already present in the spleens of unimmunized mice.
To avoid a potentially inhibitory effect of non-B cells on
RAG reexpression in the cultures and to reduce the RAG
background levels of uncultured samples, we also assessed
RAG transcript levels in sorted B220hiIgD1 and B220hi
mature B cells after in vitro culture. The combination of
anti-CD40 and IL-7 for 3 d prolonged the very low levels
of RAG transcripts already present in the uncultured,
sorted B220hiIgD1 B cell samples (Fig. 6 A, lanes 2 and 5).
However, as observed with the unsorted cultures (Fig. 5),
the level of RAG transcripts after stimulation with anti-
CD40, IL-4, and IL-7 never exceeded the levels already
present in the uncultured samples (Fig. 6 A, and data not
shown). To eliminate contaminating RAG-expressing
B220lo cells from the sorted population, B220hi cells were
analyzed. Notably, when no preexisting RAG RNA was
detectable in uncultured B cells, such as for the sorted
B220hi B cells (Fig. 6 B, lane 2), no detectable signal ap-
peared upon mitogen/cytokine stimulation (Fig. 6 B, lanes
4 and 5). In conclusion, our data suggest that cultivation in
the presence of certain stimuli (in particular IL-7) may pro-
long preexisting RAG RNA levels in uncultured splenic B
cell preparations, presumably by promoting the growth or
survival of small numbers of developing RAG1 B lympho-
cytes. However, the in vitro culture conditions tested do
not lead to reexpression of RAG transcripts in mature
RAG2 B cells to levels detectable by our assays.
Discussion
RAG1 Splenic B Cells in Immunized Mice Largely Represent
Recent BM Immigrants That Appear via an Antigen- and
CD40L-independent Process. RAG1 splenic B lineage cells
in mice immunized with NP-CGG and alum have been
proposed to be mature B cells that reexpress RAG after an
Figure 4. RAG2–GFP1 BM cells populate the spleen after immuniza-
tion. RAG2GFP/GFP spleen, RAG2GFP/GFP BM, 129 spleen, or 129 BM
cells from pooled 9–16-wk-old mice were adoptively transferred (intrave-
nously) into 5-wk-old RAG22/2 recipients which were immunized with
NP-CGG/alum (intraperitoneally) the following day or left unimmu-
nized. Splenic cells from the recipient mice were analyzed by FACS® at
day 16 for the presence of RAG2–GFP-expressing cells. Cells are gated
for the marker Ly9.1 and displayed as B220 versus RAG2–GFP. Percent-
ages of cells gated for green fluorescence out of B2201 cells (%, right) or
total live lymphocytes (%, left) are shown. After immunization, zero out
of six mice receiving spleen cells and four out of five mice receiving BM
cells showed evidence of B220lo or RAG2-GFP1 cells in the spleen. All
spleens from immunized positive control mice contained this population.
bility that transfer conditions did not allow expansion of
potential RAG1 precursors potentially present in hemato-
poietic islands of the donor spleen after immunization,
these data show that RAG1 BM cells populate the spleen
after immunization. From our combined data, we con-
cluded that immunization leads to the appearance of splenic
RAG1 B lineage cells which originate from the BM.
Lack of RAG Reexpression in Activated Mature Splenic B
Cells In Vitro. Some studies have detected induction of
RAG expression in mature splenic B cells stimulated in
vitro (17–20), whereas others have not (12, 26). To further
elucidate this phenomenon, we assayed for RAG expres-
sion in B220hi splenic B lymphocytes from RAG2–GFP
mice cultured with anti-CD40 or anti-CD40 plus IL-4 or
IL-7. No RAG expression, as measured by green fluores-
cence, was detected either in total lymphocytes or in sub-
sets defined by forward scatter or IgD under any of these
culture conditions (Fig. 5 A, and data not shown). To fur-
ther elucidate this issue, we employed RT-PCR to assay
for RAG transcripts in purified splenic B cells of normal
mice after culture for 2 d in RPMI medium alone, in the
presence of LPS, LPS plus IL-4, or in the presence of LPS
plus IL-7 (17, 19). Levels of RAG1 and 2 transcripts were
normalized to b-actin transcripts (Fig. 5 B). Whereas un-
cultured, splenic B cells showed significant RAG RNA sig-
nals (Fig. 5 B, lane 1), this level decreased in cultured, un-1751 Gartner et al.
antigen encounter in the GC (14–21), allowing additional
rearrangement of endogenous Ig genes and receptor revi-
sion (15, 21; for a review, see reference 22). However, it
was recently shown that these postimmunization RAG1
cells appeared after the administration of alum alone (23),
suggesting that these cells are not antigen specific. In this
regard, we now extend these results by showing that the
appearance of these cells does not appear to require T cell
interactions or a GC reaction, as we observed them in the
spleens of “immunized” CD40L2/2 mice. In addition, our
adoptive transfer studies indicate that the RAG1 splenic B
lineage cells in immunized older mice largely represent re-
cent immigrants from the BM. Our findings argue that the
majority of splenic RAG1 cells that appear after immuniza-
tion derive from the migration of differentiating BM
RAG1 B lineage cells to the spleen, rather than from the
reinduction of RAG in mature B cells.
Previous studies observed RAG1 cells in the GC after
immunization (11, 12, 14–17, 19, 20), suggesting that re-
ceptor revision occurs in response to the antigen. In sup-
port of this notion, studies coupling somatic mutation and
Ig re-rearrangement in human tonsil B cells and transgenic
mouse B cells also supported the existence of peripheral B
lineage cells that revise their receptors (39–41; for a review,
see reference 22). However, it was also noted that RAG1
GC cells predominantly lost Ig expression and expressed
Figure 5. Lack of RAG upregulation in
splenic B cells after in vitro stimulation. (A)
Sorted B220hi splenic B cells from
RAG2GFP/GFP and 129 wt mice were cul-
tured in vitro in RPMI medium alone (un-
stimulated) or in the presence of anti-
CD40, anti-CD40 plus IL-4, or anti-CD40
plus IL-7 for 3 d and analyzed for RAG2–
GFP expression by FACS®. Histograms of
cultured wt cells (shaded) are overlayed
with histograms of cultured RAG2GFP/GFP
cells (line). (B) Spleen cells from 10–12-wk-
old C3H mice were depleted of T cells by
treatment with anti-Thy1.2 mAbs and com-
plement. 80% of the remaining cells were B
cells and 2.3% were T cells as determined
by FACS® analysis. A second cytotoxic de-
pletion did not significantly improve the re-
moval of T cells (data not shown). The cells
were cultured as indicated. Subsequently,
RNA was isolated and used for RT-PCR
analysis of RAG1, RAG2, TdT, and l-5.
Germline e and g2b IgH transcripts were
measured to control for LPS (induction of
g2b germline transcript) and of IL-4 (induc-
tion of e germline transcript and suppression
of LPS-induced g2b germline transcript) ac-
tivity. Activity of IL-7 was determined by
its ability to promote proliferation in fetal
liver cultures (data not shown). b-Actin was
used as a control to ensure equivalent amounts of RNA. One of three similar experiments is shown. In several similar experiments using slightly different
conditions (total spleen cultures, two times the cytotoxic T cell depletion, anti-CD40 instead of LPS), RAG transcript levels in activated samples never
surpassed those already present in the uncultured cells (data not shown). (C) RT-PCR analysis of the transcript levels of GAPDH and Mb-1 in b-actin–
adjusted splenic B cell samples obtained as described in B and treated as indicated.
Figure 6. No RAG reexpression in RAG2 splenic B
cells after in vitro stimulation. (A) Sorted B220hiIgD1
splenic B cells (99% purity by FACS® reanalysis with
0.1% contaminating B220lo cells) from a pool of five
15-wk-old C3H mice were left uncultured or were
cultured in vitro for 3 d in RPMI medium as indicated.
RT-PCR analysis of the RAG1 transcript levels was
performed using b-actin for normalization. Uncultured
BM cell RNA served as a positive control. Absolute
levels of RAG transcripts in the sorted B cell samples
were z1:2,000 of those in total BM as determined by
serial dilutions (data not shown). The functional integ-
rity of these cultures was confirmed by their ability to
perform isotype class switching 4–5 d after appropriate
stimulation (data not shown). (B) Splenic B cells sorted
based on very high B220 expression were cultured in vitro. RNA was purified from uncultured cells or from samples cultured for 2 d, and RAG1 and
RAG2 transcripts were assayed by RT-PCR with high sensitivity (up to 45 cycles) using b-actin for normalization. Uncultured BM cells were analyzed
as a positive control.1752 Appearance of RAG1 BM Cells in Spleens of Immunized Mice
several pro/pre-B markers such as l-5, Vpre-B, and TdT
(14, 15, 26). One potential explanation for this common
gene expression was that the mature B cells underwent a
process of “neoteny” in which the cells reverted to a pre/
pro-B–like phenotype along with the reactivation of RAG
genes (14). However, pre-B cells in the BM also express
several standard GC B cell markers including PNA and
GL-7 (this study; 14, 37, 42, 43; for reviews, see references
44, 45), raising the possibility that BM pre-B cell immi-
grants to the spleen could be readily confused with tradi-
tional GC B cells. Correspondingly, recent studies using
NG-BAC RAG reporter mice showed no evidence of
RAG reexpression in either adoptively transferred RAG2
spleen cells or whole spleen cells after immunization (12,
23). These studies also showed that RAG1 cells present in
the spleen on day 16 after immunization did not represent
proliferating GC cells (23). Overall, our current results sup-
port the general conclusion of the latter studies, that the
majority of RAG1 cells in the spleen after immunization
do not derive from mature B cells.
Persistence of Preexisting RAG Expression Rather Than
RAG Reexpression in Mitogen/Cytokine–stimulated Splenic B
Cell Cultures. The initial notion that mature B cells could
be induced to reexpress RAG genes derived substantially
from studies that reported the induction of RAG transcripts
in mature peripheral B cells after in vitro culture in the
presence of various activators and cytokines (16–19, 21).
However, other studies have found that RAG is not in-
duced in LPS plus IL-4–treated splenic B cells (12, 26). In
this regard, we found that preexisting RAG transcript levels
did in fact decline when splenic B lineage cell populations
were cultured without stimulation or with mitogen treat-
ment alone, although the addition of cytokines, notably IL-7,
could prolong baseline RAG expression. In this context,
IL-7 is known to promote survival and/or proliferation of
RAG1 developing B cells (46–48). While the population of
RAG1 splenic B lineage cells with a pro/pre-B phenotype
decreased to levels undetectable by the RAG2–GFP re-
porter assay in 9-wk-old mice, such cells still may be the
source of the low preexisting RAG levels detected in un-
cultured splenic B cell preparations from older mice via the
more sensitive RT-PCR assay. Outgrowth of splenic pre/
pro-B cells and/or differentiation into RAG1 immature B
cells could account for the apparent RAG induction ob-
served in previous studies. Though we find no evidence for
RAG induction in splenic B cells at the population level, it
is conceivable that there could be induction of RAG in a
minor subset of B cells. Finally, preliminary studies also
suggest that our finding of RAG transcripts in cultured
IgD1 BM B cells after treatment with anti-IgM (11) may
result from the selection of preexisting RAG1 cells (Seidl,
K., unpublished data).
Why Does Alum Administration Cause BM RAG-expressing
Lymphocytes to Immigrate to the Spleen? It is thought that
adjuvants such as alum augment the immune response to
antigens by inducing the innate immune system through
similar mechanisms as natural infections (49, 50). Recent
studies of NG-BAC transgenic mice demonstrated that
both alum injection and malaria infection suppress lym-
phopoiesis in the BM, but that lymphopoiesis recovers by
day 16 accompanied by the accumulation of RAG1 splenic
cells (23). This increased production of B lineage cells, sim-
ilar to that described following sublethal irradiation (9, 10,
23), may directly contribute to the accumulation of RAG1
spleen cells. In our study, alum administration caused local
inflammation in the spleen, as evidenced by the recruitment
of granulocytes. The infiltrating granulocytes may secrete as
yet undefined cytokines that, in turn, induce the migration,
proliferation, or differentiation of BM RAG1 cells. A simi-
lar function has been described previously for macrophages
(for a review, see reference 51). This influx of developing B
cells into the spleen during an immune response raises the
question of whether such cells could play an direct or indi-
rect role in the generation of antigen-specific cells and, if
so, what mechanisms would enforce tolerance with respect
to antigen-specific cells generated in the periphery (11).
Immunization May Lead to Differentiation of BM B-Lineage
Cells in the Spleen. Studies of both unimmunized and im-
munized NG-BAC mice revealed a much greater level of
GFP1IgM1 splenic B lineage cells than we found in the
corresponding RAG2–GFP mice. Although these findings
might seem contradictory, they are in fact likely to be com-
plementary when viewed with respect to the differences in
the two reporter systems. Thus, the longer half-life of the
GFP protein versus the endogenous RAG proteins in the
NG-BAC mice may allow the detection of cells that re-
cently expressed RAG for a short period after the expres-
sion of the endogenous RAG genes was extinguished (12,
23). On the other hand, the RAG2–GFP fusion protein
appears to closely resemble endogenous RAG2 with re-
spect to expression (11). Therefore, when taken together,
the results of these two separate approaches would be quite
consistent with the notion that, in response to alum,
RAG1 pre-B and immature B cells migrate from the BM
to the spleen where they can undergo further differentia-
tion to become mature B cells.
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